Answers are grounded in this paper and cite their sources.
Psychotherapy and pharmacotherapy remain the foundations of treatment for adolescent depression. Neuromodulation, such as electroconvulsive therapy or transcranial magnetic stimulation (TMS), is a relatively new approach to pediatric care and historically has not been used much within the field of child psychiatry. Electroconvulsive therapy is an important and highly effective treatment for selected adolescents with severe depression and catatonia.1 Its use, however, requires anesthesia and specialized clinical infrastructure and remains uncommon in pediatric practice. TMS offers a different form of neuromodulation with fewer procedural requirements that may help patients with significant depression. Anhedonia, or loss of interest and pleasure, deserves particular attention because greater anhedonia is associated with more severe illness and suicidality and may predict poorer treatment response.2,3In this issue of Pediatrics, Duan et al4 report a randomized, double-blind, sham-controlled trial of individualized functional connectivity-guided intermittent theta-burst stimulation (iTBS) in adolescents with major depressive disorder who had not responded adequately to at least one antidepressant trial. Compared with sham stimulation, active iTBS produced greater improvement in depressive symptoms. Improvement in anhedonia was particularly notable. The authors also found that change in anhedonia statistically mediated a substantial proportion of the later antidepressant effect. This finding does not establish anhedonia as the mechanism of treatment response, but it raises an intriguing possibility that reward-related symptoms may be an important target for neuromodulation.The individualized targeting strategy is another important feature of this study. The investigators selected a left dorsolateral prefrontal cortex region based on its functional connectivity with the nucleus accumbens, an important component of reward circuitry. Dysfunction in this network may contribute to impaired reward processing, reduced motivation, and difficulty engaging in goal-directed behavior. The study therefore provides an example of how treatment may eventually move beyond diagnosis alone and incorporate clinically important symptoms and their underlying circuitry.iTBS also has practical advantages for adolescents. It is a form of TMS that is noninvasive, does not require anesthesia, and can be delivered in an outpatient setting. Individual iTBS stimulation sessions are considerably shorter than conventional repetitive TMS sessions. This may make a repeated treatment course easier to incorporate into school and family schedules.In 2024, the US Food and Drug Administration (FDA) first cleared a TMS system as an adjunct for treatment of major depressive disorder in patients aged 15 to 21 years.5 Unlike the adult indication that specifies inadequate improvement with prior antidepressant medication, the adolescent indication does not require failed antidepressant trials. This regulatory language should not be interpreted as a recommendation to use TMS immediately after one unsuccessful selective serotonin reuptake inhibitor (SSRI) trial. It does, however, raise an important question about when consultation should occur.For pediatricians, the distinction between consultation and treatment may be more useful than defining a specific treatment threshold. The participants studied by Duan et al4 had greater treatment complexity than many adolescents with depression managed in primary care, including psychiatric comorbidity and substantial concomitant psychotropic medication use. Many were receiving other psychotropic medications, including antipsychotics, benzodiazepines, and mood stabilizers. These findings therefore should not be interpreted as establishing iTBS as the next treatment for an otherwise uncomplicated adolescent who has had an inadequate response to one SSRI.At the same time, referral does not need to wait until treatment has become highly complex. For an adolescent with persistent depression despite adequate initial treatment, particularly when anhedonia and functional impairment remain substantial, consultation with a child psychiatrist may be reasonable. TMS centers are increasingly available across the United States, and many practices can provide treatment to adolescents aged 15 years and older. However, child psychiatrists with specific expertise in neuromodulation remain relatively scarce, and consultation with a pediatric neuromodulation specialist may require referral to a regional specialty or academic center. This consultation model may be particularly relevant to pediatric practice. Pediatricians increasingly care for adolescents with depression because access to specialty mental health care remains limited. Referral for neuromodulation consultation does not require pediatricians to determine TMS candidacy themselves. Rather, it provides another option when initial treatment has not produced sufficient recovery.Several questions remain before this approach can be incorporated more broadly into care. The interaction between neuromodulation and other treatments deserves particular study. Medications may alter response to stimulation, and concurrent psychotherapy may enhance or modify treatment effects. These questions are especially relevant given the medication complexity of participants in this trial. Development also matters. The participants ranged from 10 to 17 years, a period of substantial brain maturation. Larger studies and longer follow-up are needed to better understand developmental differences, durability of response, and cognitive safety.Duan et al4 offer an important view of how treatment for adolescent depression may evolve. Their study combines a clinically meaningful symptom, individualized neural targeting, and a noninvasive intervention. For pediatricians, the immediate implication is not that iTBS should become the next step after an antidepressant fails. It is that neuromodulation can become part of the treatment discussion when depression persists despite appropriate initial treatment. Future research should help define which patients are most likely to benefit, how neuromodulation should be combined with psychotherapy and medication, and when consultation and treatment should occur.
No takes yet. Share an insight, caveat, or question.
Yupei Pearl Hu (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: